Plasma Biomarkers for Predicting Recurrence of Atrial Fibrillation Following Cardioversion


The inventors have developed a panel of biomarkers, including various matrix metalloproteinases (MMPs) and tissue inhibitor matrix metalloproteinases (TIMPs), which can determine patients at risk for recurrent atrial fibrillation (AF). These biomarkers can pre-emptively detect treatment failure for cardioversion activities. These biomarkers can be detected and measured by performing a simple, point-of-care blood test and provide a predictive measure of recurrence.




Atrial fibrillation (AF) produces significant burdens on the health system, responsible for almost 50% of arrhythmia hospitalizations. Furthermore, patients are at increased risk for stroke by several times more than normal individuals. Medications for this disease state are challenging due to the severity of adverse effects and drug interactions. In fact, traditional cardioversion therapies are not always effective to prevent recurrent AF. There is a growing need to identify patients who would respond best to cardioversion therapy, in order to provide significant cost savings and lead to optimal treatment plans. There are no cardiac biomarkers in this market segment at present.

Advantages: Earlier identification of patients at risk for recurrent atrial fibrillation


Key Words: Atrial fibrillation, recurrent AF, arrhythmia, cardioversion, hypertension, stroke, cardiac biomarkers, diagnostic



Mukherjee, Rupak, et al. “Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion.” J Cardiovasc Transl Res. 2013 Aug; 6 (4):528-35.

Mukherjee, Rupak, et al. "Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation." The American journal of cardiology 97.4 (2006): 532-537.



Inventors:              F.G. Spinale, R. Mukherjee, M.R. Gold

Patent Status:        US Patent 8,506,499

Licensing Status:       This technology has been optioned, please contact FRD to more information or to be put in touch the current optionee.

MUSC-FRD Technology ID:    P0730


Patent Information:
For Information, Contact:
Docket BioPharma
Zucker Institute of Innovation Commercialization powered by MUSC
Rupak Mukherjee
Michael Gold
Francis Spinale
© 2024. All Rights Reserved. Powered by Inteum